Abstract
Among the recent topics in the field of liver transplantation (LT), one of the significant therapeutic breakthroughs is the introduction of direct‐acting antiviral agents (DAAs) against hepatitis C virus (HCV) infection. With cure rates close to 100%, a better proportion of LT candidates and recipients can be cured of HCV infection by DAA therapies that are simple and well‐tolerated. Other critical topics include the issue of indication of LT for patients with hepatocellular carcinoma, which has been continuously studied. Several expanded criteria beyond the Milan criteria with acceptable results have been recently reported. The role of donor‐specific antibodies (DSAs) in intractable rejection is also an important matter that has been studied. Although long recognized as an important factor in antibody‐mediated rejection and even graft survival in renal transplantation, the impact of DSAs on graft and patient survival in LT remains to be elucidated. Including the issues described above, this article focuses on recent advances in LT, management to avoid recurrence of primary diseases, optimization of immunosuppressive treatment, and extended donor criteria.
Highlights
This study presented what they suggested to be a novel paradigm for preventing the recurrence of Primary sclerosing cholangitis (PSC), which frequently recurs after ABO compatible (ABO-c) living-donor liver transplantation (LDLT)
The largest proportion of liver transplantation (LT) in adults was performed in patients with HCVrelated cirrhosis
The availability of safe and effective direct antiviral agent (DAA) to cure hepatitis C virus (HCV) infection in almost all patients regardless of the HCV genotype is currently reducing the need for LT
Summary
Liver transplantation (LT) is a prevalent treatment option for end-stage liver disease and acute liver failure, many characteristic issues remain to be solved. Hazard Associated with Liver Transplantation for Hepatocellular Carcinoma (HALTHCC) model has been recently validated by international multicenters including Japanese centers.[8] This model is a continuous score calculated as follows: (2.31*lin(AFP)) + (1.33*tumor burden score) + (0.25*MELD-Na) − (5.57*Asia). Small-for-size grafts defined as GRWR
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
